{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:17:12Z","timestamp":1788491832944,"version":"build-2803163510"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Concurrent anxiety is frequent in major depressive disorder and a shared pathophysiological mechanism between anxiety and other depressive symptoms is plausible. The serotonin 4 receptor (5-HT<jats:sub>4<\/jats:sub>R) has been implicated in both depression and anxiety. This is the first study to investigate the association between the cerebral 5-HT<jats:sub>4<\/jats:sub>R binding and anxiety in patients with depression before and after antidepressant treatment and the association to treatment response. Ninety-one drug-free patients with depression were positron emission tomography scanned with the 5-HT<jats:sub>4<\/jats:sub>R ligand [<jats:sup>11<\/jats:sup>C]-SB207145. Depression severity and concurrent anxiety was measured at baseline and throughout 8\u2009weeks of antidepressant treatment. Anxiety measures included four domains: anxiety\/somatization factor score; Generalized Anxiety Disorder 10-items (GAD-10) score; anxiety\/somatization factor score \u22657 (anxious depression) and syndromal anxious depression. Forty patients were rescanned at week 8. At baseline, we found a negative association between global 5-HT<jats:sub>4<\/jats:sub>R binding and both GAD-10 score (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) and anxiety\/somatization factor score (<jats:italic>p<\/jats:italic>\u2009=\u20090.06). Further, remitters had a higher baseline anxiety\/somatization factor score compared with non-responders (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). At rescan, patients with syndromal anxious depression had a greater change in binding relative to patients with non-syndromal depression (<jats:italic>p<\/jats:italic>\u2009=\u20090.04). Concurrent anxiety in patients with depression measured by GAD-10 score and anxiety\/somatization factor score is negatively associated with cerebral 5-HT<jats:sub>4<\/jats:sub>R binding. A lower binding may represent a subtype with reduced natural resilience against anxiety in a depressed state, and concurrent anxiety may influence the effect on the 5-HT<jats:sub>4<\/jats:sub>R from serotonergic antidepressants. The 5-HT<jats:sub>4<\/jats:sub>R is a promising neuroreceptor for further understanding the underpinnings of concurrent anxiety in patients with depression.<\/jats:p>","DOI":"10.1038\/s41398-022-02034-5","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T11:04:54Z","timestamp":1657623894000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Concurrent anxiety in patients with major depression and cerebral serotonin 4 receptor binding. A NeuroPharm-1 study"],"prefix":"10.1038","volume":"12","author":[{"given":"Kristin","family":"K\u00f6hler-Forsberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brice","family":"Ozenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren V.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asbj\u00f8rn S.","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3557-0092","authenticated-orcid":false,"given":"Elizabeth B.","family":"Landman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5467-5159","authenticated-orcid":false,"given":"Vibeke H.","family":"Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Teng","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6012-6965","authenticated-orcid":false,"given":"Anders","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7811-1825","authenticated-orcid":false,"given":"Claus","family":"Svarer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-6866","authenticated-orcid":false,"given":"Gitte M.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibe G.","family":"Frokjaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1321-8901","authenticated-orcid":false,"given":"Martin B.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"2034_CR1","doi-asserted-by":"crossref","unstructured":"Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Article difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008. www.star-d.org.","DOI":"10.1176\/appi.ajp.2007.06111868"},{"key":"2034_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol, Neurosurg, Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol, Neurosurg, Psychiatry"},{"key":"2034_CR3","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018. https:\/\/github.com\/ihmeuw\/."},{"key":"2034_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4088\/JCP.10m06176blu","volume":"72","author":"F Lamers","year":"2011","unstructured":"Lamers F, van Oppen P, Comijs HC, Smit JH, Spinhoven P, van Balkom AJ, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). J Clin psychiatry. 2011;72:341\u20138.","journal-title":"J Clin psychiatry"},{"key":"2034_CR5","doi-asserted-by":"crossref","unstructured":"Fava M, Rankin MA, Wright EC, Alpert JE, Nierenberg AA, Pava J, et al. Anxiety disorders in major depression. Compr Psychiatry. 2000;41:97\u2013102.","DOI":"10.1016\/S0010-440X(00)90140-8"},{"key":"2034_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5694\/mjao12.10628","volume":"1","author":"JWG Tiller","year":"2012","unstructured":"Tiller JWG. Depression and anxiety. Med J Aust. 2012;1:28\u201332.","journal-title":"Med J Aust"},{"key":"2034_CR7","doi-asserted-by":"crossref","unstructured":"Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety. 1996\u20131997;4:160\u20138.","DOI":"10.1002\/(SICI)1520-6394(1996)4:4<160::AID-DA2>3.0.CO;2-J"},{"key":"2034_CR8","doi-asserted-by":"publisher","unstructured":"Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008. https:\/\/doi.org\/10.1176\/appi.ajp.2007.06111868.","DOI":"10.1176\/appi.ajp.2007.06111868"},{"key":"2034_CR9","doi-asserted-by":"publisher","unstructured":"Nelson JC. Anxious depression and response to treatment. Am J Psychiatry. 2008. https:\/\/doi.org\/10.1176\/appi.ajp.2007.07121927.","DOI":"10.1176\/appi.ajp.2007.07121927"},{"key":"2034_CR10","doi-asserted-by":"publisher","unstructured":"Iscan Z, Rakesh G, Rossano S, Yang J, Zhang M, Miller J, et al. A positron emission tomography study of the serotonergic system in relation to anxiety in depression. European Neuropsychopharmacol. 2017. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.07.009.","DOI":"10.1016\/j.euroneuro.2017.07.009"},{"key":"2034_CR11","doi-asserted-by":"publisher","unstructured":"Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, et al. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Mol. Psychiatry. 2008. https:\/\/doi.org\/10.1038\/sj.mp.4002149.","DOI":"10.1038\/sj.mp.4002149"},{"key":"2034_CR12","doi-asserted-by":"publisher","unstructured":"Reimold M, Knobel A, Rapp MA, Batra A, Wiedemann K, Str\u00f6hle A, et al. Central serotonin transporter levels are associated with stress hormone response and anxiety. Psychopharmacology. 2011. https:\/\/doi.org\/10.1007\/s00213-010-1903-y.","DOI":"10.1007\/s00213-010-1903-y"},{"key":"2034_CR13","doi-asserted-by":"publisher","unstructured":"Beliveau V, Ganz M, Feng L, Ozenne B, H\u00f8jgaard L, Fisher PM, et al. A high-resolution in vivo atlas of the human brain\u2019s serotonin system. J Neurosci. 2017. https:\/\/doi.org\/10.1523\/JNEUROSCI.2830-16.2016.","DOI":"10.1523\/JNEUROSCI.2830-16.2016"},{"key":"2034_CR14","doi-asserted-by":"publisher","unstructured":"Bonaventure P, Hall H, Gommeren W, Cras P, Langlois X, Jurzak M, et al. Mapping of serotonin 5-HT4 receptor mRNA and ligand binding sites in the post-mortem human brain. Synapse. 2000. https:\/\/doi.org\/10.1002\/(SICI)1098-2396(200004)36.","DOI":"10.1002\/(SICI)1098-2396(200004)36"},{"key":"2034_CR15","doi-asserted-by":"publisher","unstructured":"Bockaert J, Claeysen S, Compan V, Dumuis A. 5-HT4 receptors. Curr Drug Targets CNS Neurol Disord. 2004. https:\/\/doi.org\/10.2174\/1568007043482615.","DOI":"10.2174\/1568007043482615"},{"key":"2034_CR16","doi-asserted-by":"publisher","unstructured":"Compan V, Zhou M, Grailhe R, Gazzara RA, Martin R, Gingrich J, et al. Attenuated response to stress and novelty and hypersensitivity to seizures in 5-HT4 receptor knock-out mice. J. Neurosci. 2004. https:\/\/doi.org\/10.1523\/JNEUROSCI.2806-03.2004.","DOI":"10.1523\/JNEUROSCI.2806-03.2004"},{"key":"2034_CR17","doi-asserted-by":"publisher","unstructured":"Faye C, Hen R, Guiard BP, Denny CA, Gardier AM, Mendez-David I, et al. Rapid anxiolytic effects of RS67333, a serotonin type 4 receptor agonist, and diazepam, a benzodiazepine, are mediated by projections from the prefrontal cortex to the dorsal raphe nucleus. Biol Psychiatry. 2020. https:\/\/doi.org\/10.1016\/j.biopsych.2019.08.009.","DOI":"10.1016\/j.biopsych.2019.08.009"},{"key":"2034_CR18","doi-asserted-by":"publisher","unstructured":"Mendez-David I, David DJ, Darcet F, Wu MV, Kerdine-R\u00f6mer S, Gardier AM, et al. Rapid anxiolytic effects of a 5-HT4 receptor agonist are mediated by a neurogenesis-independent mechanism. Neuropsychopharmacology. 2014. https:\/\/doi.org\/10.1038\/npp.2013.332.","DOI":"10.1038\/npp.2013.332"},{"key":"2034_CR19","doi-asserted-by":"publisher","unstructured":"Chen BK, Mendez-David I, Luna VM, Faye C, Gardier AM, David DJ, et al. Prophylactic efficacy of 5-HT4R agonists against stress. Neuropsychopharmacology. 2019. https:\/\/doi.org\/10.1038\/s41386-019-0540-3.","DOI":"10.1038\/s41386-019-0540-3"},{"key":"2034_CR20","doi-asserted-by":"publisher","unstructured":"Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S, et al. Serotonin(4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action. Neuron. 2007. https:\/\/doi.org\/10.1016\/j.neuron.2007.07.041.","DOI":"10.1016\/j.neuron.2007.07.041"},{"key":"2034_CR21","doi-asserted-by":"publisher","unstructured":"Murphy SE, Wright LC, Browning M, Cowen PJ, Harmer CJ. A role for 5-HT4 receptors in human learning and memory. Psychol Med. Published 2019. https:\/\/doi.org\/10.1017\/S0033291719002836.","DOI":"10.1017\/S0033291719002836"},{"key":"2034_CR22","doi-asserted-by":"publisher","unstructured":"Haahr ME, Fisher PM, Jensen CG, Frokjaer VG, Mahon BM, Madsen K, et al. Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: A [11C]SB207145 PET study. Mol Psychiatry. 2014. https:\/\/doi.org\/10.1038\/mp.2013.147.","DOI":"10.1038\/mp.2013.147"},{"key":"2034_CR23","doi-asserted-by":"publisher","unstructured":"Licht CL, Marcussen AB, Wegener G, Overstreet DH, Aznar S, Knudsen GM. The brain 5-HT4 receptor binding is down-regulated in the Flinders Sensitive Line depression model and in response to paroxetine administration. J. Neurochemistry. 2009. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06050.x.","DOI":"10.1111\/j.1471-4159.2009.06050.x"},{"key":"2034_CR24","doi-asserted-by":"publisher","unstructured":"Vidal R, Valdiz\u00e1n EM, Mostany R, Pazos A, Castro E Long-term treatment with fluoxetine induces desensitization of 5-HT 4 receptor-dependent signalling and functionality in rat brain. J. Neurochemistry. 2009. https:\/\/doi.org\/10.1111\/j.1471-4159.2009.06210.x.","DOI":"10.1111\/j.1471-4159.2009.06210.x"},{"key":"2034_CR25","doi-asserted-by":"publisher","unstructured":"Rebholz H, Friedman E, Castello J. Alterations of expression of the serotonin 5-HT4 receptor in brain disorders. Int J Mol Sci. 2018. https:\/\/doi.org\/10.3390\/ijms19113581.","DOI":"10.3390\/ijms19113581"},{"key":"2034_CR26","doi-asserted-by":"publisher","unstructured":"K\u00f6hler-Forsberg K, Ozenne B, Landman EB, Larsen SV, Poulsen AS, Dam VH, et al. Evidence for a serotonergic subtype of major depressive disorder: A NeuroPharm-1 study. medRxiv. https:\/\/doi.org\/10.1101\/2021.06.17.21258740.","DOI":"10.1101\/2021.06.17.21258740"},{"key":"2034_CR27","doi-asserted-by":"publisher","unstructured":"Amig\u00f3 J, D\u00edaz A, Pilar-Cu\u00e9llar F, Vidal R, Mart\u00edn A, Compan V, et al. The absence of 5-HT4 receptors modulates depression- and anxiety-like responses and influences the response of fluoxetine in olfactory bulbectomised mice: adaptive changes in hippocampal neuroplasticity markers and 5-HT1A autoreceptor. Neuropharmacology. 2016. https:\/\/doi.org\/10.1016\/j.neuropharm.2016.08.037.","DOI":"10.1016\/j.neuropharm.2016.08.037"},{"key":"2034_CR28","doi-asserted-by":"publisher","unstructured":"K\u00f6hler-Forsberg K, Jorgensen A, Dam VH, Stenb\u00e6k DS, Fisher PM, Ip CT, et al. Predicting treatment outcome in major depressive disorder using serotonin 4 receptor PET brain imaging, functional MRI, cognitive-, EEG-based, and peripheral biomarkers: a NeuroPharm open label clinical trial Protocol. Front Psychiatry. 2020. https:\/\/doi.org\/10.3389\/fpsyt.2020.00641.","DOI":"10.3389\/fpsyt.2020.00641"},{"key":"2034_CR29","doi-asserted-by":"publisher","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR (text revision). Wiley. 2000. https:\/\/doi.org\/10.1002\/9780470479216.corpsy0271.","DOI":"10.1002\/9780470479216.corpsy0271"},{"key":"2034_CR30","unstructured":"Bech P, Lunde M, Und\u00e9n M. An inventory for the measurement of generalised anxiety distress symptoms, the GAD-10 Inventory. Acta Psychiatrica Belg. 2005;105:111\u20138."},{"key":"2034_CR31","doi-asserted-by":"crossref","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22\u201333.","DOI":"10.1037\/t18597-000"},{"key":"2034_CR32","doi-asserted-by":"publisher","unstructured":"Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001. https:\/\/doi.org\/10.1016\/S0893-133X(01)00298-6.","DOI":"10.1016\/S0893-133X(01)00298-6"},{"key":"2034_CR33","first-page":"115","volume":"1","author":"P Cleary","year":"1977","unstructured":"Cleary P, Guy W. Factor analysis of the hamilton depression scale. Drugs Exp Clin Res. 1977;1:115\u201320.","journal-title":"Drugs Exp Clin Res"},{"key":"2034_CR34","doi-asserted-by":"publisher","unstructured":"Ionescu DF, Niciu MJ, Henter ID, Zarate CA. Defining anxious depression: a review of the literature. CNS Spectrums. 2013. https:\/\/doi.org\/10.1017\/S1092852913000114.","DOI":"10.1017\/S1092852913000114"},{"key":"2034_CR35","doi-asserted-by":"publisher","unstructured":"Braund TA, Palmer DM, Williams LM, Harris AWF. Characterising anxiety in major depressive disorder and its use in predicting antidepressant treatment outcome: An iSPOT-D report. Aust N Z J Psychiatry. 2019. https:\/\/doi.org\/10.1177\/0004867419835933.","DOI":"10.1177\/0004867419835933"},{"key":"2034_CR36","doi-asserted-by":"publisher","unstructured":"Timmerby N, Andersen JH, S\u00f8ndergaard S, \u00d8stergaard SD, Bech P. A systematic review of the clinimetric properties of the 6-item version of the Hamilton Depression Rating Scale (HAM-D6). Psychother Psychosom. 2017. https:\/\/doi.org\/10.1159\/000457131.","DOI":"10.1159\/000457131"},{"key":"2034_CR37","doi-asserted-by":"publisher","unstructured":"Fisher PM, Holst KK, Mc Mahon B, Haahr ME, Madsen K, Gillings N, et al. 5-HTTLPR status predictive of neocortical 5-HT 4 binding assessed with [11C]SB207145 PET in humans. NeuroImage. 2012. https:\/\/doi.org\/10.1016\/j.neuroimage.2012.05.013.","DOI":"10.1016\/j.neuroimage.2012.05.013"},{"key":"2034_CR38","doi-asserted-by":"publisher","unstructured":"Madsen K, Torstensen E, Holst KK, Haahr ME, Knorr U, Frokjaer VG, et al. Familial risk for major depression is associated with lower striatal 5-HT<inf>4<\/inf> receptor binding. Int J Neuropsychopharmacol. 2015. https:\/\/doi.org\/10.1093\/ijnp\/pyu034.","DOI":"10.1093\/ijnp\/pyu034"},{"key":"2034_CR39","doi-asserted-by":"publisher","unstructured":"Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing pet images. J Comput Assist Tomogr. 1992. https:\/\/doi.org\/10.1097\/00004728-199207000-00024.","DOI":"10.1097\/00004728-199207000-00024"},{"key":"2034_CR40","doi-asserted-by":"publisher","unstructured":"Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugb\u00f8l S, Fr\u00f8kjar VG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. NeuroImage. 2005. https:\/\/doi.org\/10.1016\/j.neuroimage.2004.10.017.","DOI":"10.1016\/j.neuroimage.2004.10.017"},{"key":"2034_CR41","doi-asserted-by":"publisher","unstructured":"Marner L, Gillings N, Comley RA, Baar\u00e9 WF, Rabiner EA, Wilson AA, et al. Kinetic modeling of 11C-SB207145 binding to 5-HT4 receptors in the human brain in vivo. J Nucl Med. 2009. https:\/\/doi.org\/10.2967\/jnumed.108.058552.","DOI":"10.2967\/jnumed.108.058552"},{"key":"2034_CR42","doi-asserted-by":"publisher","unstructured":"Marner L, Gillings N, Madsen K, Erritzoe D, Baar\u00e9 WF, Svarer C, et al. Brain imaging of serotonin 4 receptors in humans with [11C]SB207145-PET. NeuroImage. 2010. https:\/\/doi.org\/10.1016\/j.neuroimage.2010.01.054.","DOI":"10.1016\/j.neuroimage.2010.01.054"},{"key":"2034_CR43","doi-asserted-by":"publisher","unstructured":"Holst KK, Budtz-J\u00f8rgensen E. Linear latent variable models: the lava-package. Comput Stat. 2013. https:\/\/doi.org\/10.1007\/s00180-012-0344-y.","DOI":"10.1007\/s00180-012-0344-y"},{"key":"2034_CR44","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1002\/sim.5990","volume":"32","author":"A Dmitrienko","year":"2013","unstructured":"Dmitrienko A, D\u2019Agostino Sr R. Traditional multiplicity adjustment methods in clinical trials. Stat Med. 2013;32:5172\u2013218. https:\/\/doi.org\/10.1002\/sim.5990","journal-title":"Stat Med"},{"key":"2034_CR45","doi-asserted-by":"publisher","unstructured":"Fisher PM, Holst KK, Adamsen D, Klein AB, Frokjaer VG, Jensen PS, et al. BDNF Val66met and 5-HTTLPR polymorphisms predict a human in vivo marker for brain serotonin levels. Hum Brain Mapp. 2015. https:\/\/doi.org\/10.1002\/hbm.22630.","DOI":"10.1002\/hbm.22630"},{"key":"2034_CR46","doi-asserted-by":"publisher","unstructured":"Madsen K, Haahr MT, Marner L, Keller SH, Baar\u00e9 WF, Svarer C, et al. Age and sex effects on 5-HT 4 receptors in the human brain: A 11 CSB207145 PET study. J Cereb Blood Flow Metab. 2011. https:\/\/doi.org\/10.1038\/jcbfm.2011.11.","DOI":"10.1038\/jcbfm.2011.11"},{"key":"2034_CR47","doi-asserted-by":"publisher","unstructured":"Madsen K, Marner L, Haahr M, Gillings N, Knudsen GM. Mass dose effects and in vivo affinity in brain PET receptor studies - a study of cerebral 5-HT 4 receptor binding with [11C]SB207145. Nucl Med Biol. 2011. https:\/\/doi.org\/10.1016\/j.nucmedbio.2011.04.006.","DOI":"10.1016\/j.nucmedbio.2011.04.006"},{"key":"2034_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nature19318","volume":"537","author":"CA Marcinkiewcz","year":"2016","unstructured":"Marcinkiewcz CA, Mazzone CM, D\u2019Agostino G, Halladay LR, Hardaway JA, DiBerto JF, et al. Serotonin engages an anxiety and fear-promoting circuit in the extended amygdala. Nature. 2016;537:97\u2013101.","journal-title":"Nature"},{"key":"2034_CR49","doi-asserted-by":"publisher","unstructured":"Boulenger JP, Hermes A, Huusom AKT, Weiller E. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: Escitalopram vs paroxetine. Curr Med Res Opin. 2010. https:\/\/doi.org\/10.1185\/03007990903482467.","DOI":"10.1185\/03007990903482467"},{"key":"2034_CR50","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1034\/j.1600-0447.2003.00120.x","volume":"108","author":"PR Joyce","year":"2003","unstructured":"Joyce PR, Mulder RT, Luty SE, McKenzie JM, Rae AM. A differential response to nortriptyline and fluoxetine in melancholic depression: The importance of age and gender. Acta Psychiatr Scandinavica. 2003;108:20\u201323.","journal-title":"Acta Psychiatr Scandinavica"},{"key":"2034_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0165-0327(02)00083-6","volume":"76","author":"RT Mulder","year":"2003","unstructured":"Mulder RT, Watkins WGA, Joyce PR, Luty SE. Age may affect response to antidepressants with serotonergic and noradrenergic actions. J Affect Disord. 2003;76:143\u20139.","journal-title":"J Affect Disord"},{"key":"2034_CR52","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1034\/j.1600-0447.2002.02432.x","volume":"106","author":"G Parker","year":"2002","unstructured":"Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scandinavica. 2002;106:168\u201370.","journal-title":"Acta Psychiatr Scandinavica"},{"key":"2034_CR53","unstructured":"Goldberger C, Guelfi JD, Sheehan DV. Assessment of anxiety in clinical trials with depressed patients using the Hamilton depression rating scale. Psychopharmacology Bulletin. 2011;44(3):34-\u201350."},{"key":"2034_CR54","doi-asserted-by":"publisher","unstructured":"Broen MP, Moonen AJ, Kuijf ML, Dujardin K, Marsh L, Richard IH, et al. Factor analysis of the Hamilton depression rating scale in Parkinson\u2019s disease. Parkinsonism and Relat Disord. 2015. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.11.016.","DOI":"10.1016\/j.parkreldis.2014.11.016"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02034-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02034-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02034-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T19:44:39Z","timestamp":1669232679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-022-02034-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2034"],"URL":"https:\/\/doi.org\/10.1038\/s41398-022-02034-5","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"23 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MBJ has given talks sponsored by H. Lundbeck and Boehringer Ingelheim. GMK has served as expert consultant for SAGE Therapeutics and Sanos. VGF has served as consultant for SAGE Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"273"}}